The poster will be available on ... are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations ...

Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq ... today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win ® technology platform, today announced three poster ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

The poster titled "Immunization with Clostridium ... as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance ...

The forums — which typically include talks, poster presentations ... Plenty of other regular biotech social gatherings exist, including networking event Biotech Tuesday and a biotech softball ...

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American ... Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual ...

The event is taking place on Prague, Czech Republic, from 20 to 22 March 2017 and PCI Biotech will present a poster on 21 March, 17:30 local time (CET). The poster will be presented by Dr. Tone ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq ... today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report ...

The clinical trial is sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103. About IOB-032/PN-E40 Phase 2 Basket Trial in ...